For years, industry leaders treated pharma market access as just another item on the launch checklist. Regulatory approval? Check. Price negotiation? Check. Launch and move on? Job done… or so it seemed.
But in 2025, the landscape is shifting quickly. Payers are more sceptical, budgets are tighter, and patients are better informed, more vocal, and demanding higher standards of care. Pharma commercialisation is moving beyond blockbuster launches towards a more strategic, integrated approach: one where access is built in from the start.
If you suspect that your market access playbook hasn’t kept pace with the world around it, you’re certainly not alone. In this article, we explore how forward-thinking organisations are rewriting the rules, and why now is the optimal time to raise the bar.
Beyond the deal: Securing lasting access
Reimbursement in a major market might once have felt like the finish line, whereas now it’s just one step in a much longer journey. Regulators and health technology assessment (HTA) bodies are revisiting decisions more frequently. Market access is now central to post-launch performance, with companies increasingly expected to prove both clinical and economic merit after launch. Meanwhile, biosimilars, policy changes, and agile competitors can chip away at market share faster than ever.
Take expensive gene therapies as an example. Some companies have had to go far beyond traditional submissions, negotiating risk-sharing deals, committing to extended monitoring, and even helping health systems manage upfront costs. This new access landscape is no longer a one-off negotiation, but an evolving partnership that requires constant engagement and adaptability.
Static dossiers are out. Dynamic value stories are in.
The next decade demands that market access teams move away from the ‘one-off’ health economic model tucked into a static dossier. Instead, value demonstration must become an ongoing process, anticipating questions, updating findings, and equipping field teams and medical colleagues to communicate relevance in ways that resonate locally.
One common example is from the field of infectious diseases: when a curative treatment was introduced, initial pricing sparked backlash despite its transformative potential. Over time, the company responded by partnering with governments, offering tailored pricing in lower-income regions, and sharing outcomes data to demonstrate cost savings for health systems. That switch, from defending a price to modelling a compelling therapeutic proposition, was what ultimately fostered confidence. It’s a clear example of what modern pharma commercialisation demands: real-world evidence, market sensitivity, and a readiness to revisit assumptions continuously.
What’s influencing access strategy in 2025 (and beyond)?
To stay ahead, market access leaders must navigate a fast-changing environment, driven by reframed expectations, rising data demands, and increasingly localised needs.
As complexity grows, three trends emerge that are critical to enduring success.
- Managed entry agreements are now standard practice
Contracts that tie payment to performance, like risk-sharing and outcomes-based models, have become widely adopted, particularly for high-cost therapies with uncertain multi-year data. To succeed, teams need the skills to negotiate, monitor, and adapt these agreements across the product lifecycle.
This is where pharma market access becomes agile: a strategy that advances in real time as new data emerges and payer expectations transition.
- Data is your strongest currency
Trial results alone fail to meet payer expectations, as payers now look for clear proof of benefit, such as reductions in hospitalisations, improvements in quality of life, and progression trends throughout the course of treatment.
Leading companies are investing early in disease registries, patient-reported outcomes, and data partnerships to stay ahead of access pressures. In one chronic condition, a pharma leader monitored patient treatment journeys for ten years, using that data to reinforce pricing arguments and strengthen relationships with HCPs.
- Global value messages don’t translate everywhere
It’s tempting to roll out a one-size-fits-all narrative, but it rarely delivers. Local stakeholders care about different things. North American payers might focus on budget impact, while European HTAs may zero in on workforce productivity or cumulative cost savings.
Pharma commercialisation in 2025 demands local nuance. Equip your teams with the tools and autonomy to shape messages that resonate in each market.
Rethinking your approach to market access
Future-ready access strategies don’t happen by accident. They’re assembled through deliberate choices, planning smarter, acting sooner, and staying flexible.
If you’re reassessing your market access approach, here are the foundational moves that matter most.
– Engage early: Think Phase II, not post-Phase III
Too many teams wait until the pivotal trial readout to think about access. But by then, it’s often too late to course-correct. Integrate payer perspectives into your development plans promptly, including endpoints, comparators, and population selection.
Some companies are already involving HTA bodies during Phase II to align on evidence needs, resulting in speedier approvals, fewer surprises, and smoother commercialisation.
– Break down silos between access, medical, and commercial
High-performing teams integrate market access from day one. When medical, commercial, and access teams collaborate, they ensure consistent claims, well-founded justification, and post-approval strategies that hold up under scrutiny.
This kind of cross-functional alignment is essential to successful pharma commercialisation, especially for complex therapies.
– Invest in skills (and partnerships) that go beyond price
Many access teams were historically structured around traditional pricing and negotiation. The next generation needs deeper skills in health economics, data science, dynamic contracting, and local policy navigation. But mindset matters, too. The best leaders see payers and policymakers as allies in shaping effective, reliable patient care.
That modification opens doors to unconventional collaborations, from tech partnerships to creating shared success metrics with patient groups.
– Aim for upheld integrity, not short-term wins
Chasing the maximum price at launch can backfire, triggering rebates, negative press, and strained relationships. A more workable approach balances early revenue goals with clear affordability arguments, good public perception, and well-established market trust.
Some companies are already tailoring pricing based on patient subgroups or local budget impact. It’s a smart way to show payers: we get it, and we’re in this for the long haul.
Final thoughts: Innovation is not enough
We’re entering an era of powerful, personalised medicines, but if our approach to pharma market access remains stuck in the past, innovation will not reach the people who need it.
The organisations that will thrive in 2025 and beyond are those that treat access as a strategic pillar rather than a hurdle. That means thinking proactively, grounding decisions in data, and forging genuine partnerships across the healthcare system.
If your access strategy looks the same as it did five years ago, it’s time to ask yourself: ‘What needs to change?’ Patients, payers, and policymakers have already moved on, and it’s time we did, too.
Contact us
